Variable | Remission (n = 12) | Non-remission (n = 21) | Crude OR (95% CI) | P | Adjusted OR (95% CI) | P |
---|---|---|---|---|---|---|
Age | ||||||
< 55 | 10 | 13 | 1 | 1 | 0.408 | |
≥ 55 | 2 | 8 | 3.08 (0.53–17.80) | 0.209 | 4.07 (0.15–113.53) | |
Sex | ||||||
Female | 7 | 12 | 1 | 1 | 0.696 | |
Male | 5 | 9 | 1.05 (0.25–4.42) | 0.947 | 1.44 (0.23–8.89) | |
Pathologic type | ||||||
Papillary | 11 | 18 | 1 | 1 | 0.473 | |
Follicular | 1 | 3 | 1.83 (0.17–19.90) | 0.618 | 0.26 (0.01–10.10) | |
Stage | ||||||
I + II | 11 | 16 | 1 | 1 | 0.685 | |
III + IV | 1 | 5 | 3.44 (0.35–33.61) | 0.289 | 0.45 (0.01–20.84) | |
TSH-stimulated Tg | ||||||
≤ 50 | 7 | 6 | 1 | 1 | 0.279 | |
> 50 | 5 | 14 | 3.27 (0.73–14.55) | 0.120 | 2.87 (0.43–19.31) | |
99mTc-3PRGD2 uptake by metastases | ||||||
Not avid | 6 | 2 | 1 | 1 | 0.041* | |
Avid | 6 | 19 | 9.50 (1.50–60.11) | 0.017* | 9.36 (1.10–79.83) | |
131I uptake by metastases | ||||||
Not avid | 8 | 11 | 1 | 1 | 0.833 | |
Avid | 4 | 10 | 1.82 (0.42–7.94) | 0.427 | 0.80 (0.11–6.12) |